Crude risks for clinical events according to the baseline BNP values
| Number of patients with event | Unadjusted | ||
| (Cumulative 5-year incidence) | HR (95% CI) | P values | |
| All-cause death | |||
| Group 1 | 40 (23.2%) | 1 (reference) | |
| Group 2 | 31 (39.5%) | 2.00 (1.24 to 3.19) | 0.005 |
| Group 3 | 22 (68.3%) | 3.46 (2.02 to 5.77) | <0.001 |
| Group 4 | 26 (56.1%) | 4.37 (2.62 to 7.16) | <0.001 |
| Cardiovascular death | |||
| Group 1 | 14 (8.0%) | 1 (reference) | |
| Group 2 | 15 (22.9%) | 2.88 (1.38 to 6.05) | 0.005 |
| Group 3 | 12 (44.2%) | 5.54 (2.51 to 12.04) | <0.001 |
| Group 4 | 17 (42.1%) | 8.70 (4.24 to 18.15) | <0.001 |
| Aortic valve-related death | |||
| Group 1 | 10 (6.4%) | 1 (reference) | |
| Group 2 | 10 (18.1%) | 2.72 (1.11 to 6.65) | 0.03 |
| Group 3 | 7 (28.7%) | 4.70 (1.70 to 12.32) | 0.004 |
| Group 4 | 9 (26.5%) | 6.92 (2.72 to 17.40) | <0.001 |
| Sudden death | |||
| Group 1 | 6 (3.5%) | 1 (reference) | |
| Group 2 | 4 (4.7%) | 1.85 (0.47 to 6.53) | 0.36 |
| Group 3 | 1 (8.3%) | 1.20 (0.06 to 7.09) | 0.87 |
| Group 4 | 4 (12.1%) | 5.17 (1.29 to 18.80) | 0.02 |
| HF hospitalisation | |||
| Group 1 | 19 (9.5%) | 1 (reference) | |
| Group 2 | 16 (25.7%) | 2.43 (1.23 to 4.74) | 0.01 |
| Group 3 | 14 (46.3%) | 5.59 (2.73 to 11.17) | <0.001 |
| Group 4 | 14 (38.3%) | 5.98 (42.92 to 11.96) | <0.001 |
Number of patients with event was counted through the entire follow-up period, while the cumulative incidence was estimated at 5 year. Aortic valve-related death included aortic procedure-related death, sudden death and death due to heart failure. HF hospitalisation was defined as hospitalisation due to worsening heart failure requiring intravenous drug therapy.
BNP, B-type natriuretic peptide; HF, heart failure.